Renata Gontijo Lima

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Emma Guttman‐Yassky, Diamant Thaçi et al. · New England Journal of Medicine · 2023 · 314 citations

Medicine, Dermatology, Pharmacology +17

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg et al. · JAMA Dermatology · 2023 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski et al. · British Journal of Dermatology · 2020 · 117 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )

Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños et al. · British Journal of Dermatology · 2020 · 108 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11